Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
Higher Order Structure 2017
Share |


Thank you to all who participated and helped make HOS 2017 a success!

Mark your calendars now for HOS 2018: April 9-11, 2018 in Providence, Rhode Island, USA.

Protein higher order structure (HOS) includes the secondary, tertiary and quaternary structures of a protein, which comprise the three dimensional structures that are necessary for structure and function. Proteins in solution are dynamic molecules which can sample an ensemble of structures in solution, and have molecular properties which results in differing propensities to self associate and form a range of species from oligomers to visible particles. Changes in the HOS of proteins can  contribute to the quality attributes, and potentially safety, efficacy, and pharmacokinetic properties of protein therapeutica. Regulatory agencies require assessment of HOS to assess how protein structure is affected by manufacturing, storage and delivery; and analytical biosimilarity is an important part of evaluating potential changes in clinical safety and efficacy. There are many biophysical characterization methods and tools used in monitoring the attributes of protein therapeutics such as conformation and higher order structure.  However, since most biophysical analyses provide ensemble average structural information of the molecules, it is essential to evaluate if the observed changes are significant and are tracking changes in CQAs, and cannot be attributed to assay or process variability. Use of the appropriate biophysical method, method development and qualification to characterize the quality attributes at different stages of the product lifecycle are therefore a matter of interest and debate for a wide range of audiences. This Symposium will focus on various biophysical methods for assessment of protein HOS, as well as the applications of the appropriate tools during the different stages of protein therapeutic development and biosimilarity assessments, the theory and practice of biophysics, technical data from academia and industry as well as method qualification, validation and setting specifications.

Topics will include the following:

      • Consequences of HOS Changes

      • Development: Process/product development/commercialization/post-approval

      • Legacy Methods

      • New and Emerging Technologies

      • Protein Therapeutics Discovery and Candidate Selection

      • Young Scientist

We urge professionals from the following functions to not only attend but to fully engage in these important discussions: Discovery Sciences Process, Product Development Formulation Development Quality Assurance, Quality Control, Regulatory Affairs, Immunology Molecular, Biological Consequences, H/D Exchange and Cell Biology Analytical Development Manufacturing Sciences Clinical Pharmacology.

 

 

Want more information? Check out the "More in this Section" dropdown box at the top of the page!
Or contact CASSS at 510-428-0740 or info@casss.org


 
more Calendar

7/17/2017 » 7/18/2017
CMC Strategy Forum Summer 2017

9/17/2017 » 9/22/2017
CE Pharm and Mass Spec 2017

Featured Members
Julia Edwards, AllerganJulia Edwards is an Executive Director with Allergan.

Membership Software Powered by YourMembership  ::  Legal